The granted trademark protection means that the brand name Zeqmelit® is given national protection in the United Kingdom. The trademark protection covers the goods and services included in the international registration.

The registration protection runs according to the dates that apply to the international registration and is renewed in connection with the renewal of the same, which must take place no later than January 9, 2033.

"The fact that we are now supplementing the trademark protection in the EU with the UK is of great importance for our upcoming market launch of Zeqmelit®. The approval means that we effectively protect the company's intangible assets," says Jonas Jönmark, CEO of AcuCort.

For further information please contact:

Jonas Jönmark, vd, AcuCort AB

Telefon: 070 365 5400

Epost: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in Sweden, Denmark, Norway and Finland. All in all, it strengthens the company's assessment that the time until commercialization can be relatively short. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit  (http://www.acucort.se)www.acucort.se.